tamsulosin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 2562 106133-20-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamsulosin
  • tamsulosin hydrochloride
  • tamsulosin HCl
  • LY-253352
A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA.
  • Molecular weight: 408.51
  • Formula: C20H28N2O5S
  • CLOGP: 2.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.88
  • ALOGS: -4.79
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.03 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.62 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 15, 1997 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrolithiasis 174.85 15.42 91 7485 36656 53304834
Urinary tract infection 84.24 15.42 134 7442 239769 53101721
Multiple sclerosis relapse 74.46 15.42 57 7519 44796 53296694
Urinary retention 58.12 15.42 41 7535 28425 53313065
Residual urine volume increased 44.61 15.42 7 7569 24 53341466
Ligament pain 32.24 15.42 7 7569 175 53341315
Rheumatoid arthritis 31.12 15.42 4 7572 314527 53026963
Renal colic 29.91 15.42 10 7566 1317 53340173
Respiratory tract inflammation 28.65 15.42 8 7568 575 53340915
Drug ineffective 25.99 15.42 48 7528 817197 52524293
Progressive multifocal leukoencephalopathy 25.98 15.42 18 7558 12111 53329379
Disorganised speech 23.96 15.42 8 7568 1049 53340441
Pertussis 23.77 15.42 7 7569 609 53340881
Multiple sclerosis 23.77 15.42 24 7552 27129 53314361
Renal stone removal 22.88 15.42 5 7571 129 53341361
Urinary tract obstruction 22.84 15.42 9 7567 1892 53339598
Chorioretinitis 22.14 15.42 6 7570 386 53341104
Sinus pain 21.18 15.42 9 7567 2290 53339200
Hydronephrosis 20.53 15.42 14 7562 9182 53332308
Immune reconstitution inflammatory syndrome 19.98 15.42 12 7564 6334 53335156
Flank pain 19.37 15.42 16 7560 13980 53327510
Iris disorder 19.04 15.42 4 7572 85 53341405
Product use issue 18.04 15.42 52 7524 139532 53201958
Hypertensive nephropathy 16.66 15.42 5 7571 464 53341026
Central nervous system stimulation 16.21 15.42 3 7573 32 53341458
Erythropenia 15.72 15.42 4 7572 201 53341289
Product use in unapproved indication 15.65 15.42 43 7533 112246 53229244

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Iris disorder 742.82 10.73 201 165432 163 32347730
Urinary retention 403.43 10.73 683 164950 35014 32312879
Dizziness 362.40 10.73 2057 163576 207561 32140332
Fall 344.77 10.73 1934 163699 194267 32153626
Orthostatic hypotension 283.43 10.73 486 165147 25164 32322729
Cataract operation complication 256.41 10.73 73 165560 86 32347807
Syncope 255.89 10.73 1022 164611 89102 32258791
Iridocele 224.50 10.73 58 165575 30 32347863
Drug abuse 215.60 10.73 70 165563 80173 32267720
Urinary tract infection 205.20 10.73 880 164753 79191 32268702
Dysuria 180.70 10.73 396 165237 24614 32323279
Floppy iris syndrome 177.73 10.73 66 165567 265 32347628
Toxicity to various agents 173.81 10.73 408 165225 177633 32170260
Procedural complication 160.37 10.73 156 165477 4544 32343349
Benign prostatic hyperplasia 146.82 10.73 242 165391 12122 32335771
Pollakiuria 140.20 10.73 301 165332 18443 32329450
Idiopathic pulmonary fibrosis 119.33 10.73 129 165504 4266 32343627
Completed suicide 111.69 10.73 187 165446 92330 32255563
Product prescribing error 108.62 10.73 281 165352 19436 32328457
Off label use 105.12 10.73 1026 164607 305294 32042599
Drug ineffective 99.18 10.73 1368 164265 382109 31965784
Urinary incontinence 96.74 10.73 256 165377 17951 32329942
Haematuria 95.54 10.73 493 165140 47868 32300025
Micturition urgency 93.54 10.73 126 165507 5260 32342633
Nocturia 93.43 10.73 169 165464 9125 32338768
Retrograde ejaculation 92.25 10.73 42 165591 310 32347583
Asthenia 91.71 10.73 1699 163934 234245 32113648
Multiple organ dysfunction syndrome 91.13 10.73 134 165499 69720 32278173
Prostatomegaly 85.03 10.73 116 165517 4902 32342991
Fatigue 80.61 10.73 2346 163287 348355 31999538
Drug resistance 80.02 10.73 11 165622 22954 32324939
Atrial fibrillation 78.74 10.73 925 164708 115779 32232114
Febrile neutropenia 72.86 10.73 337 165296 119229 32228664
Urine flow decreased 72.16 10.73 56 165577 1193 32346700
Prostate cancer 69.16 10.73 300 165333 27106 32320787
Presyncope 68.52 10.73 219 165414 17082 32330811
Intentional overdose 67.84 10.73 67 165566 41534 32306359
Pupillary disorder 67.58 10.73 32 165601 261 32347632
Product monitoring error 67.18 10.73 74 165559 2500 32345393
Hypotension 65.69 10.73 1501 164132 214609 32133284
Prostatic disorder 65.11 10.73 80 165553 3044 32344849
Hallucination 62.10 10.73 470 165163 52149 32295744
Cytomegalovirus infection 61.96 10.73 26 165607 25438 32322455
Drug dependence 60.41 10.73 22 165611 23462 32324431
Confusional state 58.78 10.73 1040 164593 142075 32205818
Treatment failure 58.37 10.73 68 165565 39095 32308798
Prostatic specific antigen increased 56.92 10.73 172 165461 13015 32334878
Balance disorder 56.24 10.73 369 165264 39090 32308803
Abdominal pain lower 52.82 10.73 136 165497 9377 32338516
Urogenital haemorrhage 52.54 10.73 33 165600 493 32347400
Miosis 52.06 10.73 128 165505 8576 32339317
Cardio-respiratory arrest 48.57 10.73 136 165497 55853 32292040
Suicide attempt 47.32 10.73 76 165557 38168 32309725
Labelled drug-drug interaction medication error 47.23 10.73 155 165478 12258 32335635
General physical health deterioration 46.73 10.73 836 164797 114423 32233470
Product substitution issue 45.87 10.73 137 165496 10299 32337594
Drug reaction with eosinophilia and systemic symptoms 45.67 10.73 59 165574 32426 32315467
Pyrexia 45.49 10.73 1262 164371 318706 32029187
Respiratory arrest 45.49 10.73 48 165585 28860 32319033
Bradycardia 43.35 10.73 556 165077 71006 32276887
Alanine aminotransferase increased 43.28 10.73 229 165404 78250 32269643
Dyspnoea 42.97 10.73 2254 163379 359791 31988102
Memory impairment 41.97 10.73 351 165282 40128 32307765
Leukopenia 41.81 10.73 161 165472 59961 32287932
Ocular procedural complication 41.66 10.73 15 165618 54 32347839
Overdose 41.65 10.73 266 165367 86811 32261082
Ejaculation failure 40.96 10.73 34 165599 800 32347093
Bladder disorder 40.46 10.73 63 165570 3005 32344888
Gait disturbance 38.75 10.73 600 165033 79808 32268085
Cystitis 37.54 10.73 118 165515 9121 32338772
Peritonitis 37.52 10.73 35 165598 22295 32325598
Constipation 37.45 10.73 875 164758 125498 32222395
Bone marrow failure 37.07 10.73 61 165572 30343 32317550
Rheumatoid arthritis 36.59 10.73 111 165522 44433 32303460
Bladder spasm 36.04 10.73 33 165600 889 32347004
Thrombocytopenia 36.01 10.73 535 165098 147764 32200129
Haemophagocytic lymphohistiocytosis 35.98 10.73 7 165626 11328 32336565
Lower urinary tract symptoms 35.50 10.73 19 165614 206 32347687
Loss of consciousness 35.33 10.73 605 165028 82102 32265791
Cataract operation 35.22 10.73 37 165596 1183 32346710
Aspergillus infection 34.99 10.73 8 165625 11566 32336327
Nephrolithiasis 34.92 10.73 249 165384 27105 32320788
Cardiac arrest 34.36 10.73 321 165312 96455 32251438
Cataract 33.75 10.73 225 165408 23958 32323935
Bladder cancer 33.72 10.73 122 165511 10134 32337759
Peripheral swelling 33.70 10.73 512 165121 67833 32280060
Orbital myositis 33.64 10.73 16 165617 132 32347761
Neutropenia 33.11 10.73 517 165116 141658 32206235
Prostatitis 32.82 10.73 79 165554 5221 32342672
Muscular weakness 32.77 10.73 507 165126 67422 32280471
Disseminated intravascular coagulation 31.65 10.73 43 165590 23133 32324760
Hormone receptor positive breast cancer 31.64 10.73 10 165623 21 32347872
Graft versus host disease 31.63 10.73 8 165625 10798 32337095
Hepatic failure 31.43 10.73 86 165547 35594 32312299
Nipple pain 31.32 10.73 26 165607 612 32347281
Erectile dysfunction 31.03 10.73 190 165443 19649 32328244
Full blood count decreased 30.56 10.73 169 165464 16841 32331052
Vitreous loss 30.42 10.73 8 165625 5 32347888
Testicular swelling 29.90 10.73 37 165596 1418 32346475
Haematochezia 29.20 10.73 317 165316 38891 32309002
Hospice care 29.12 10.73 76 165557 5283 32342610
Plasmapheresis 29.03 10.73 20 165613 352 32347541
Contusion 28.94 10.73 279 165354 33189 32314704
Septic shock 28.45 10.73 220 165413 68769 32279124
Haematoma 28.39 10.73 226 165407 25458 32322435
Urinary tract obstruction 28.39 10.73 59 165574 3532 32344361
Priapism 28.38 10.73 72 165561 4919 32342974
Urosepsis 28.36 10.73 128 165505 11762 32336131
Dacryocystitis 28.29 10.73 8 165625 9 32347884
Vomiting 28.25 10.73 950 164683 234607 32113286
Product use in unapproved indication 28.13 10.73 296 165337 86908 32260985
Intentional product use issue 28.09 10.73 115 165518 42096 32305797
Oedema peripheral 27.62 10.73 769 164864 113322 32234571
Hypertonic bladder 27.59 10.73 35 165598 1376 32346517
Hepatic vein dilatation 27.00 10.73 16 165617 214 32347679
Intentional self-injury 26.82 10.73 19 165614 13881 32334012
Myelosuppression 26.72 10.73 13 165620 11663 32336230
Synovitis 26.64 10.73 11 165622 10867 32337026
Needle fatigue 26.34 10.73 20 165613 412 32347481
Head injury 26.27 10.73 167 165466 17496 32330397
Mucosal inflammation 26.27 10.73 85 165548 33349 32314544
Immune reconstitution inflammatory syndrome 26.25 10.73 8 165625 9551 32338342
Faeces discoloured 26.19 10.73 147 165486 14730 32333163
Dementia 26.09 10.73 136 165497 13250 32334643
Right atrial hypertrophy 25.97 10.73 18 165615 320 32347573
Drug intolerance 25.82 10.73 150 165483 50085 32297808
Pneumocystis jirovecii pneumonia 25.78 10.73 35 165598 18835 32329058
Coma 25.39 10.73 121 165512 42491 32305402
Atrial septal defect 25.35 10.73 3 165630 7022 32340871
Wound 25.13 10.73 133 165500 13034 32334859
Hot flush 24.57 10.73 150 165483 15496 32332397
Vertigo 24.33 10.73 209 165424 24074 32323819
Thrombotic microangiopathy 24.19 10.73 9 165624 9473 32338420
Bladder catheterisation 24.14 10.73 22 165611 589 32347304
Infusion related reaction 23.52 10.73 136 165497 45463 32302430
Hepatotoxicity 23.38 10.73 39 165594 19298 32328595
Hypoacusis 23.34 10.73 148 165485 15493 32332400
Drug hypersensitivity 23.32 10.73 250 165383 73150 32274743
Haematospermia 23.21 10.73 18 165615 383 32347510
Gait spastic 23.11 10.73 20 165613 499 32347394
Incontinence 22.99 10.73 72 165561 5554 32342339
Blood urine present 22.89 10.73 110 165523 10375 32337518
Aortic stenosis 22.74 10.73 60 165573 4198 32343695
Pathogen resistance 22.67 10.73 10 165623 9500 32338393
Myocardial infarction 22.63 10.73 478 165155 125198 32222695
Adverse drug reaction 22.56 10.73 216 165417 25645 32322248
Factitious disorder 22.20 10.73 9 165624 48 32347845
Prostatic mass 22.17 10.73 8 165625 29 32347864
Candida infection 22.12 10.73 32 165601 16771 32331122
Dizziness postural 22.05 10.73 73 165560 5799 32342094
Peritonitis bacterial 21.69 10.73 19 165614 12477 32335416
Micturition disorder 21.61 10.73 38 165595 2006 32345887
Platypnoea 21.57 10.73 8 165625 32 32347861
Urinary hesitation 21.56 10.73 41 165592 2300 32345593
Milk-alkali syndrome 21.50 10.73 20 165613 550 32347343
Dry mouth 21.31 10.73 202 165431 23917 32323976
Liver palpable 21.20 10.73 15 165618 276 32347617
Stress 21.19 10.73 57 165576 23725 32324168
Cornea verticillata 21.00 10.73 8 165625 35 32347858
Seizure 20.80 10.73 388 165245 103466 32244427
Poisoning 20.56 10.73 16 165617 11142 32336751
C-reactive protein increased 20.48 10.73 152 165481 47950 32299943
Palpitations 20.32 10.73 276 165357 35693 32312200
Ascites 20.12 10.73 121 165512 40070 32307823
Bladder neck obstruction 20.11 10.73 11 165622 125 32347768
Relapsing-remitting multiple sclerosis 20.02 10.73 20 165613 602 32347291
Acute respiratory distress syndrome 19.98 10.73 64 165569 25189 32322704
Brain oedema 19.85 10.73 22 165611 12938 32334955
Gait inability 19.80 10.73 172 165461 19875 32328018
Atrial enlargement 19.76 10.73 15 165618 309 32347584
Dysgeusia 19.74 10.73 208 165425 25323 32322570
Cytomegalovirus viraemia 19.65 10.73 5 165628 6722 32341171
Cytokine release syndrome 19.63 10.73 24 165609 13511 32334382
Pallor 19.41 10.73 190 165443 22691 32325202
Transaminases increased 19.40 10.73 64 165569 24964 32322929
Post micturition dribble 19.18 10.73 6 165627 12 32347881
Subdural haematoma 19.09 10.73 170 165463 19783 32328110
Pancreatitis 19.03 10.73 115 165518 38036 32309857
Iris atrophy 18.95 10.73 9 165624 74 32347819
Lacunar stroke 18.90 10.73 11 165622 142 32347751
Acute hepatic failure 18.80 10.73 23 165610 12946 32334947
Blood bilirubin increased 18.77 10.73 118 165515 38666 32309227
Idiopathic interstitial pneumonia 18.77 10.73 11 165622 144 32347749
Hepatitis C 18.54 10.73 25 165608 13493 32334400
Aortic valve stenosis 18.49 10.73 37 165596 2155 32345738
Aspartate aminotransferase increased 18.48 10.73 233 165400 66196 32281697
Perineal pain 18.24 10.73 22 165611 821 32347072
Agranulocytosis 18.22 10.73 60 165573 23417 32324476
Bronchopulmonary aspergillosis 18.08 10.73 26 165607 13661 32334232
Transient ischaemic attack 18.04 10.73 206 165427 25588 32322305
Hepatomegaly 18.03 10.73 16 165617 10441 32337452
Back pain 17.99 10.73 714 164919 110339 32237554
Periorbital haematoma 17.89 10.73 15 165618 358 32347535
Stomal hernia 17.81 10.73 10 165623 120 32347773
Bladder outlet obstruction 17.77 10.73 12 165621 204 32347689
Post transplant lymphoproliferative disorder 17.70 10.73 4 165629 5830 32342063
Iris haemorrhage 17.51 10.73 5 165628 6 32347887
Therapeutic product effect incomplete 17.43 10.73 131 165502 41210 32306683
Hepatitis 17.41 10.73 62 165571 23631 32324262
Intentional product misuse 17.29 10.73 110 165523 35941 32311952
Toxic epidermal necrolysis 17.13 10.73 51 165582 20542 32327351
Therapy non-responder 17.04 10.73 97 165536 32557 32315336
Congenital hiatus hernia 16.99 10.73 13 165620 271 32347622
Prostatism 16.91 10.73 13 165620 273 32347620
Herpes simplex 16.84 10.73 3 165630 5171 32342722
Tendon pain 16.67 10.73 41 165592 2747 32345146
Psoriatic arthropathy 16.53 10.73 42 165591 17818 32330075
Psychotic disorder 16.41 10.73 61 165572 22959 32324934
Bladder discomfort 16.40 10.73 9 165624 103 32347790
Prostatic obstruction 16.36 10.73 10 165623 142 32347751
Breast tenderness 16.36 10.73 20 165613 757 32347136
Haematotoxicity 16.35 10.73 7 165626 6769 32341124
Urinary tract disorder 16.35 10.73 34 165599 2036 32345857
Genital swelling 16.29 10.73 11 165622 187 32347706
Hip fracture 16.27 10.73 110 165523 11765 32336128
Product use issue 16.26 10.73 181 165452 52596 32295297
Guillain-Barre syndrome 16.24 10.73 63 165570 5411 32342482
Phaeochromocytoma malignant 16.22 10.73 8 165625 72 32347821
Prostatic operation 16.22 10.73 14 165619 348 32347545
Urinary bladder haemorrhage 16.15 10.73 31 165602 1751 32346142
Pancytopenia 16.12 10.73 348 165285 90887 32257006
Transurethral prostatectomy 16.06 10.73 14 165619 353 32347540
Hydronephrosis 16.04 10.73 93 165540 9430 32338463
Megakaryocytes increased 15.93 10.73 7 165626 47 32347846
Cardiogenic shock 15.90 10.73 53 165580 20609 32327284
Akathisia 15.80 10.73 8 165625 7017 32340876
Inferior vena cava dilatation 15.79 10.73 19 165614 707 32347186
Serum ferritin abnormal 15.77 10.73 12 165621 248 32347645
Dacryostenosis acquired 15.75 10.73 11 165622 198 32347695
Therapy partial responder 15.74 10.73 3 165630 4927 32342966
Status epilepticus 15.67 10.73 23 165610 11983 32335910
Resting tremor 15.56 10.73 18 165615 642 32347251
Tuberculosis 15.48 10.73 13 165620 8716 32339177
Nephropathy toxic 15.48 10.73 23 165610 11923 32335970
Intestinal haemorrhage 15.46 10.73 45 165588 3334 32344559
Ageusia 15.22 10.73 93 165540 9609 32338284
Drug ineffective for unapproved indication 15.09 10.73 30 165603 13882 32334011
Mydriasis 15.02 10.73 7 165626 6439 32341454
Puncture site haematoma 15.01 10.73 10 165623 166 32347727
Diabetic neuropathy 14.98 10.73 51 165582 4109 32343784
Lymphopenia 14.98 10.73 32 165601 14424 32333469
Posterior reversible encephalopathy syndrome 14.95 10.73 16 165617 9560 32338333
Renal tubular disorder 14.94 10.73 4 165629 5198 32342695
Burning feet syndrome 14.93 10.73 8 165625 87 32347806
Sperm concentration zero 14.92 10.73 4 165629 3 32347890
Macular degeneration 14.90 10.73 33 165600 2064 32345829
Angle closure glaucoma 14.86 10.73 19 165614 753 32347140
Hepatic enzyme increased 14.84 10.73 119 165514 36918 32310975
Bovine tuberculosis 14.83 10.73 9 165624 126 32347767
Breast disorder male 14.82 10.73 5 165628 14 32347879
Right ventricular hypertrophy 14.76 10.73 21 165612 923 32346970
Gallbladder hypofunction 14.57 10.73 5 165628 15 32347878
Neurogenic bladder 14.57 10.73 29 165604 1683 32346210
Urethral pain 14.50 10.73 6 165627 34 32347859
Dysphagia 14.48 10.73 413 165220 61063 32286830
Metabolic acidosis 14.43 10.73 135 165498 40564 32307329
Arteriovenous fistula 14.40 10.73 18 165615 697 32347196
Residual urine volume increased 14.39 10.73 4 165629 4 32347889
Colitis ulcerative 14.35 10.73 42 165591 17009 32330884
Dysstasia 14.33 10.73 104 165529 11382 32336511
Inflammation 14.32 10.73 70 165563 24423 32323470
Faecaloma 14.32 10.73 55 165578 4701 32343192
Diabetes mellitus 14.29 10.73 154 165479 45019 32302874
Hypertriglyceridaemia 14.26 10.73 14 165619 8705 32339188
Benign gastrointestinal neoplasm 14.24 10.73 9 165624 136 32347757
Klebsiella infection 14.13 10.73 12 165621 8000 32339893
Hepatic function abnormal 14.13 10.73 153 165480 44687 32303206
Hepatic steatosis 14.12 10.73 39 165594 16094 32331799
Acidosis 13.94 10.73 21 165612 10825 32337068
Myxoedema coma 13.92 10.73 12 165621 298 32347595
Hyponatraemic syndrome 13.91 10.73 11 165622 241 32347652
Pulmonary function test abnormal 13.90 10.73 32 165601 2054 32345839
Hepatocellular injury 13.87 10.73 74 165559 25244 32322649
Loss of bladder sensation 13.83 10.73 7 165626 67 32347826
Respiratory distress 13.78 10.73 114 165519 35132 32312761
Cardiotoxicity 13.78 10.73 4 165629 4928 32342965
Pain in extremity 13.75 10.73 739 164894 118162 32229731
Calculus bladder 13.74 10.73 20 165613 898 32346995
Chronic obstructive pulmonary disease 13.63 10.73 335 165298 48418 32299475
Blood pressure systolic 13.50 10.73 4 165629 6 32347887
Metastases to neck 13.50 10.73 4 165629 6 32347887
Suprapubic pain 13.49 10.73 13 165620 374 32347519
Breast enlargement 13.47 10.73 14 165619 442 32347451
Arteriosclerotic gangrene 13.40 10.73 7 165626 72 32347821
Testicular pain 13.34 10.73 39 165594 2897 32344996
Ventricular enlargement 13.24 10.73 14 165619 451 32347442
Sepsis 13.16 10.73 668 164965 158166 32189727
Muscle spasms 13.14 10.73 460 165173 69958 32277935
Psoriasis 13.12 10.73 161 165472 45962 32301931
Prostate cancer metastatic 13.03 10.73 62 165571 5823 32342070
Venoocclusive liver disease 13.03 10.73 11 165622 7354 32340539
Hyponatraemia 12.99 10.73 483 165150 74030 32273863
Hepatic cytolysis 12.92 10.73 14 165619 8319 32339574
Subdural hygroma 12.90 10.73 12 165621 330 32347563
Vertigo CNS origin 12.85 10.73 3 165630 0 32347893
Prostatic acid phosphatase increased 12.85 10.73 3 165630 0 32347893
Iris injury 12.85 10.73 3 165630 0 32347893
Pupillary block 12.85 10.73 3 165630 0 32347893
Blood creatine phosphokinase increased 12.84 10.73 159 165474 45317 32302576
Bronchial secretion retention 12.83 10.73 21 165612 1045 32346848
Flatulence 12.83 10.73 153 165480 19202 32328691
Paraplegia 12.81 10.73 37 165596 2729 32345164
Cystitis haemorrhagic 12.80 10.73 5 165628 5109 32342784
Colitis 12.74 10.73 111 165522 33840 32314053
Osteonecrosis 12.54 10.73 43 165590 16579 32331314
Disease recurrence 12.50 10.73 41 165592 16023 32331870
Injection site pain 12.44 10.73 108 165525 32950 32314943
Spinal fracture 12.32 10.73 70 165563 7046 32340847
Drug withdrawal syndrome 12.31 10.73 57 165576 20174 32327719
Choroidal detachment 12.29 10.73 12 165621 351 32347542
Pulmonary tuberculosis 12.29 10.73 5 165628 4984 32342909
Dental restoration failure 12.28 10.73 5 165628 27 32347866
Ventricular fibrillation 12.25 10.73 46 165587 17264 32330629
Invasive ductal breast carcinoma 12.18 10.73 4 165629 10 32347883
Multiple system atrophy 12.09 10.73 10 165623 234 32347659
Oesophageal rupture 12.09 10.73 13 165620 427 32347466
Femoral artery aneurysm 12.08 10.73 9 165624 180 32347713
Systemic infection 11.90 10.73 31 165602 2152 32345741
Frostbite 11.89 10.73 6 165627 57 32347836
Stoma site oedema 11.85 10.73 5 165628 30 32347863
BK virus infection 11.85 10.73 5 165628 4876 32343017
Blood glucose fluctuation 11.78 10.73 46 165587 3963 32343930
Bladder tamponade 11.74 10.73 14 165619 516 32347377
Bronchial wall thickening 11.60 10.73 19 165614 946 32346947
Stomatitis 11.60 10.73 140 165493 40089 32307804
Pharyngeal cancer 11.58 10.73 5 165628 32 32347861
Bladder obstruction 11.53 10.73 15 165618 605 32347288
Hepatic necrosis 11.52 10.73 3 165630 3972 32343921
Respiratory depression 11.51 10.73 32 165601 13179 32334714
Urogenital disorder 11.46 10.73 6 165627 62 32347831
Radiation inflammation 11.46 10.73 8 165625 144 32347749
Taste disorder 11.45 10.73 51 165582 4660 32343233
Accidental exposure to product 11.44 10.73 25 165608 11177 32336716
Executive dysfunction 11.31 10.73 9 165624 199 32347694
Bedridden 11.31 10.73 44 165589 3784 32344109
Hepatocellular carcinoma 11.26 10.73 22 165611 10248 32337645
Haemorrhage urinary tract 11.25 10.73 26 165607 1673 32346220
Lower respiratory tract infection 11.24 10.73 95 165538 29148 32318745
Inappropriate antidiuretic hormone secretion 11.14 10.73 102 165531 11961 32335932
Tendon discomfort 11.12 10.73 10 165623 263 32347630
Diarrhoea 11.10 10.73 2064 163569 362738 31985155
Drug eruption 11.08 10.73 55 165578 19111 32328782
Wrong schedule 11.00 10.73 8 165625 154 32347739
Hypoxia 10.98 10.73 193 165440 51939 32295954
Lichen sclerosus 10.98 10.73 4 165629 15 32347878
Dyspnoea exertional 10.98 10.73 268 165365 38693 32309200
Serotonin syndrome 10.97 10.73 55 165578 19062 32328831
Wound haematoma 10.91 10.73 6 165627 69 32347824
Iris adhesions 10.91 10.73 9 165624 210 32347683
Blood pressure decreased 10.90 10.73 339 165294 50741 32297152
International normalised ratio increased 10.88 10.73 327 165306 48708 32299185
Anorectal operation 10.79 10.73 3 165630 3 32347890
Inadequate osteointegration 10.78 10.73 4 165629 16 32347877
Tenosynovitis 10.78 10.73 3 165630 3800 32344093
Aplastic anaemia 10.77 10.73 13 165620 7360 32340533
Visual impairment 10.75 10.73 231 165402 32657 32315236

Pharmacologic Action:

SourceCodeDescription
ATC G04CA02 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA52 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA53 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA54 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Oligozoospermia contraindication 88311004
Cataract surgery contraindication 110473004
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Pregnancy, function contraindication 289908002
Dizziness contraindication 404640003
Breastfeeding (mother) contraindication 413712001
Intraoperative floppy iris syndrome contraindication 418801006
High-Grade Prostate Cancer contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.71 acidic
pKa2 8.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR Ki 7.89 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.87 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.08 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 10.54 CHEMBL
D(3) dopamine receptor GPCR Ki 9.55 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 8.10 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 10.24 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.21 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 10.52 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.17 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 10.15 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.90 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.70 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 6.03 CHEMBL

External reference:

IDSource
4024076 VUID
N0000022081 NUI
D01024 KEGG_DRUG
106463-17-6 SECONDARY_CAS_RN
4021051 VANDF
4024076 VANDF
C0257343 UMLSCUI
CHEBI:9398 CHEBI
CHEMBL836 ChEMBL_ID
CHEMBL1200914 ChEMBL_ID
D000077409 MESH_DESCRIPTOR_UI
DB00706 DRUGBANK_ID
129211 PUBCHEM_CID
488 IUPHAR_LIGAND_ID
6750 INN_ID
G3P28OML5I UNII
236495 RXNORM
171693 MMSL
20642 MMSL
5541 MMSL
d04121 MMSL
006115 NDDF
006116 NDDF
108559004 SNOMEDCT_US
108560009 SNOMEDCT_US
372509005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FLOMAX HUMAN PRESCRIPTION DRUG LABEL 1 0024-5837 CAPSULE 0.40 mg ORAL NDA 30 sections
JALYN HUMAN PRESCRIPTION DRUG LABEL 2 0173-0809 CAPSULE 0.40 mg ORAL NDA 29 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2996 CAPSULE 0.40 mg ORAL ANDA 19 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7995 CAPSULE 0.40 mg ORAL ANDA 26 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8055 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2076 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6401 CAPSULE 0.40 mg ORAL ANDA 27 sections
Dutasteride and Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 10370-280 CAPSULE 0.40 mg ORAL ANDA 28 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-280 CAPSULE 0.40 mg ORAL ANDA 18 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10544-550 CAPSULE 0.40 mg ORAL ANDA 17 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-298 CAPSULE 0.40 mg ORAL ANDA 17 sections
FLOMAX HUMAN PRESCRIPTION DRUG LABEL 1 16590-489 CAPSULE 0.40 mg ORAL NDA 28 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 16714-713 CAPSULE 0.40 mg ORAL ANDA 26 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 33261-839 CAPSULE 0.40 mg ORAL ANDA 17 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 33342-159 CAPSULE 0.40 mg ORAL ANDA 27 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42254-012 CAPSULE 0.40 mg ORAL ANDA 17 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-264 CAPSULE 0.40 mg ORAL ANDA 19 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-725 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-947 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-013 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 43353-019 CAPSULE 0.40 mg ORAL ANDA 26 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-663 CAPSULE 0.40 mg ORAL ANDA 19 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-1846 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-3646 CAPSULE 0.40 mg ORAL ANDA 29 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-4906 CAPSULE 0.40 mg ORAL ANDA 29 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-5553 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-740 CAPSULE 0.40 mg ORAL ANDA 30 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50436-0598 CAPSULE 0.40 mg ORAL ANDA 27 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51655-677 CAPSULE 0.40 mg ORAL ANDA 14 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52959-034 CAPSULE 0.40 mg ORAL ANDA 17 sections